PARD (Poniard Pharmaceuticals) Loans Receivable: $0.00 Mil (As of Sep. 2011)


What is Poniard Pharmaceuticals Loans Receivable?

Poniard Pharmaceuticals PARD Loans Receivable is $0.00 Mil as of Sep. 2011.

Poniard Pharmaceuticals's Loans Receivable for the quarter that ended in Sep. 2011 was $0.00 Mil.

Poniard Pharmaceuticals Loans Receivable Related Terms

Poniard Pharmaceuticals Loans Receivable Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Loans Receivable Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Poniard Pharmaceuticals Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Poniard Pharmaceuticals (PARD) has a Loans Receivable of $0.00 Mil as of Sep. 2011. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Loans Receivable too high?
Poniard Pharmaceuticals' current Loans Receivable is $0.00 Mil.
How does Poniard Pharmaceuticals' Loans Receivable compare to OBMP and NSPX?
Poniard Pharmaceuticals' Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Loans Receivable is $0.00 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.